Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CELive EventsScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Amit K. Verma, MBBS

Advertisement

Articles by Amit K. Verma, MBBS

Rachel Zeig-Owens, DrPH, MPH

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

ByRachel Zeig-Owens, DrPH, MPH,Amit K. Verma, MBBS
August 5th 2022

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

Advertisement

Latest Updated Articles

  • Rachel Zeig-Owens, DrPH, MPH
    New Cancer Study Results Confirm Lasting Effects on 9/​11 First Responders

    August 5th 2022



Advertisement
Advertisement

Trending on OncLive

1

JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPC

2

Cesalatamig Monotherapy Shows Dose-Dependent Activity in PD-(L)1 Inhibitor–Experienced NSCLC

3

Dr Moser on Outcomes for WTX-124 ± Pembrolizumab in Advanced Immune-Sensitive Solid Tumors

4

Dr Banks on the Feasibility of Lifileucel in Select Metastatic Sarcomas

5

UV1 Vaccine Data Keep hTERT in Focus as an Immunotherapy Target in Recurrent Ovarian Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us